We agree that amendment of the language of the NIH Guideline Appendices as pro- 
posed by the Commissioner would serve to ameliorate the cost of implementing 
unwieldy and unnecessary containment measures by industry. Such action would 
not, in our opinion, lead to decreased safety margins for employees of corpora- 
tions engaged in fermentation production of recombinant molecules or lead to 
increased risk to public health and welfare. 
Moreover, relief from unnecessary costs of meeting BL1-LS compliance at large 
scale could help to increase the industry's international competitiveness in 
the rapidly-advancing area of recombinant DNA production technology. 
Accordingly, we support the proposed substitution of the language recited in 
51 FR 45652 for Sections I-A, 1 1 1 -A , III-A-2, and Appendices C- II, C-III and 
C-IV of the NIH Guidelines for Research Involving Recombinant DNA Molecules. 
Si ncerely 
Richard L. Hinman 
Recombinant DNA Research, Volume 1 1 
[279] 
